Carmine Vitale

Carmine Vitale

Auto-generated profile, based on publicly available information

Carmine Vitale

Department of Medical, Motor and Wellbeing Sciences, University of Naples Parthenope, 80133 Naples, Italy

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2016 in The Lancet Neurology
Verified
Journal Article
Closed access
PBPaolo Barone
Paolo Barone
GSGabriella Santangelo
Gabriella Santangelo
MAMarianna Amboni
Marianna Amboni
MPMaria Teresa Pellecchia
Maria Teresa Pellecchia
CVCarmine Vitale
Carmine Vitale

15 October 2021 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
ALAnnamaria LANDOLFI
Annamaria LANDOLFI
Carlo RicciardiCarlo Ricciardi
Carlo Ricciardi
Leandro DonisiLeandro Donisi
Leandro Donisi
Giuseppe CesarelliGiuseppe Cesarelli
Giuseppe Cesarelli
Jacopo TroisiJacopo Troisi
Jacopo Troisi
MAMarianna Amboni
Marianna Amboni
Background: Parkinson’s disease is the second most frequent neurodegenerative disorder. Its diagnosis is challenging and mainly relies on clinical aspects. At present, no biomarker is available to obtain a diagnosis of certainty in vivo. Objective: The present review aims at describing machine learning algorithms as they have been variably applied to different aspects of Parkinson’s disease diagnosis and characterization. Methods: A systematic search was conducted on PubMed in December 2019, resulting in 230 publications obtained with the following search query: “Machine Learning” “AND” “Parkinson Disease”. Results: The obtained publications were divided into 6 categories, based on different application fields: “Gait Analysis - Motor Evaluation”, “Upper Limb Motor and Tremor Evaluation”, “Handwriting and typing evaluation”, “Speech and Phonation evaluation”, “Neuroimaging and Nuclear Medicine evaluation”, “Metabolomics application”, after excluding the papers of general topic. As a result, a total of 166 articles were analyzed after elimination of papers written in languages other than English or not directly related to the selected topics. Conclusion: Machine learning algorithms are computer-based statistical approaches that can be trained and are able to find common patterns from big amounts of data. The machine learning approaches can help clinicians in classifying patients according to several variables at the same time.

1 March 2017 in Journal of the Neurological Sciences
Verified
Journal Article
Closed access
GSGabriella Santangelo
Gabriella Santangelo
FPFausta Piscopo
Fausta Piscopo
PBPaolo Barone
Paolo Barone
CVCarmine Vitale
Carmine Vitale

3 November 2023 in European Journal of Neurology
Verified
Journal Article
Open access
GMGianpaolo Maggi
Gianpaolo Maggi
CGChiara Giacobbe
Chiara Giacobbe
FIFederica Iannotta
Federica Iannotta
GSGabriella Santangelo
Gabriella Santangelo
CVCarmine Vitale
Carmine Vitale
Background and Purpose: Obstructive sleep apnea (OSA) frequently occurs in Parkinson Disease (PD), probably caused by upper airway dysfunctions or shared pathogenetic mechanisms. OSA may precede PD diagnosis or worsen throughout its course, but its relationship with clinical features and dopaminergic medication remains unclear. This meta‐analysis aimed to provide a reliable estimate of OSA prevalence in the PD population (PD‐OSA) and to clarify its clinical associated factors to help clinicians in understanding the underlying pathophysiological mechanisms.Methods: A systematic literature search was performed up to April 2023 using the PubMed, Scopus, and PsycINFO databases. Articles were included if they provided data on PD patients with and without OSA. Pooled prevalence for PD‐OSA was calculated using the proportions of PD participants diagnosed with OSA. Demographic and clinical features associated with PD‐OSA were explored by comparing PD patients with and without OSA.Results: Seventeen studies were included in the meta‐analysis. Pooled OSA prevalence was 45% of a total sample of 1448 PD patients and was associated with older age, male sex, higher body mass index (BMI), more severe motor disturbances and periodic limb movements, reduced risk of rapid eye movement sleep behavior disorder, intake of dopamine agonists, and worse excessive daytime sleepiness. No relationship emerged with cognitive functioning and neuropsychiatric manifestations.Conclusions: OSA affects nearly half of PD patients as a secondary outcome of predisposing factors such as older age and higher BMI in addition to PD‐related motor impairment. Future studies should focus on determining the impact of both clinical features and dopaminergic medication on the development of PD‐OSA.

18 January 2023 in Neurological Sciences
Verified
Journal Article
Open access
PDF file
GMGianpaolo Maggi
Gianpaolo Maggi
ADAlfonsina D'Iorio
Alfonsina D'Iorio
EAEdoardo Nicolò Aiello
Edoardo Nicolò Aiello
BPBarbara Poletti
Barbara Poletti
NTNicola Ticozzi
Nicola Ticozzi
GSGabriella Santangelo
Gabriella Santangelo
Introduction: Depression is one of the most disabling neuropsychiatric manifestations of Parkinson’s disease (PD) and requires proper screening and diagnosis because it affects the overall prognosis and quality of life of patients. This study aimed to assess the psychometric and diagnostic properties of the Beck Depression Inventory-II (BDI-II) in an Italian PD cohort. Materials and methods: Fifty consecutive outpatients with PD underwent the Italian version of the BDI-II and other questionnaires to evaluate anxiety and apathetic symptoms. Patients’ caregivers completed the depression/dysphoria domain of the Neuropsychiatric Inventory (NPI-D). We evaluated the internal consistency, convergent and divergent validity, and factorial structure of BDI-II. Sensitivity, specificity, positive and negative predictive values, and likelihood ratios were computed using ROC analyses, and an optimal cutoff was defined using the Youden index. Results: The BDI-II proved to be internally consistent (Cronbach’s α = 0.840) and substantially met the bi-factorial structure. Regarding construct validity, the BDI-II was substantially related to anxiety measures, but not to apathy. With the combination of the NPI-D and anxiety score used as the gold standard, the BDI-II overall showed good accuracy (AUC = 0.859) with adequate sensitivity (75%) and specificity (87%). The optimal cutoff point was defined at 14.50. Conclusions: We provide evidence of the psychometric and diagnostic properties of the Italian version of the BDI-II as a screening tool for depression in patients with PD. The BDI-II was found to be reliable and valid for the measurement of depression in patients with PD; therefore, it is available for use in clinical research and practice.

28 February 2024 in Journal of Neurology
Verified
Journal Article
Open access
PDF file
GMGianpaolo Maggi
Gianpaolo Maggi
FLFrancis Loayza
Francis Loayza
CVCarmine Vitale
Carmine Vitale
GSGabriella Santangelo
Gabriella Santangelo
IOIgnacio Obeso
Ignacio Obeso
Background: Although apathy and impulse control disorders (ICDs) are considered to represent opposite extremes of a continuum of motivated behavior (i.e., hypo- and hyperdopaminergic behaviors), they may also co-occur in Parkinson’s disease (PD). Objectives: We aimed to explore the co-occurrence of ICDs and apathy and its neural correlates analyzing gray matter (GM) changes in early untreated PD patients. Moreover, we aimed to investigate the possible longitudinal relationship between ICDs and apathy and their putative impact on cognition during the first five years of PD. Methods: We used the Parkinson’s Progression Markers Initiative (PPMI) database to identify the co-occurrence of apathy and ICDs in 423 early drug-naïve PD patients at baseline and at 5-year follow-up. Baseline MRI volumes and gray matter changes were analyzed between groups using voxel-based morphometry. Multi-level models assessed the longitudinal relationship (across five years) between apathy and ICDs and cognitive functioning. Results: At baseline, co-occurrence of apathy and ICDs was observed in 23 patients (5.4%). This finding was related to anatomical GM reduction along the cortical regions involved in the limbic circuit and cognitive control systems. Longitudinal analyses indicated that apathy and ICDs were related to each other as well as to the combined use of levodopa and dopamine agonists. Worse apathetic and ICDs states were associated with poorer executive functions. Conclusions: Apathy and ICDs are joint non-exclusive neuropsychiatric disorders also in the early stages of PD and their co-occurrence was associated with GM decrease in several cortical regions of the limbic circuit and cognitive control systems.